Gilead Sciences Stock Drops 2 Percent on $805 Million Trading Volume Ranking 87th Amid $202 Million Kickback Settlement

Generated by AI AgentAinvest Market Brief
Tuesday, Apr 29, 2025 7:53 pm ET1min read

On April 29, 2025,

(GILD) experienced a 2.00% decline in its stock price, with a trading volume of $805 million, ranking 87th in the day's market activity.

Gilead Sciences has reached a settlement with the Department of Justice, agreeing to pay $202 million to resolve allegations of kickbacks. The settlement addresses claims that the company used doctor speaker programs as incentives to boost prescriptions for its HIV medications. The majority of the settlement, $177 million, will go to the federal government, with the remaining amount distributed to individual states. The alleged activities occurred between 2011 and 2017.

Analysts have varied opinions on Gilead's future. The average one-year price target for

is $113.94, with projections ranging from $92.00 to $140.00. This suggests a potential upside of 7.36% from the current stock price. Additionally, 30 brokerage firms rate as "Outperform," with an average recommendation of 2.0 on a scale where 1 indicates a Strong Buy and 5 suggests a Sell.

In contrast, the GuruFocus GF Value metric for Gilead Sciences is $83.42, indicating a potential downside of 21.4% from the current share price. This metric evaluates the fair trading value based on historical trading multiples, past business growth, and future performance estimates.

Comments



Add a public comment...
No comments

No comments yet